Home » Business News » 2013 » April » April 9, 2013

Resolutions of the Ordinary General Meeting of Shareholders of Basilea Pharmaceutica Ltd.

April 9, 2013 - Basel, Switzerland

Basilea Pharmaceutica Ltd. (SIX: BSLN)reported that shareholders approved all agenda items proposed at today'sOrdinary General Meeting of Shareholders for the financial year 2012. Atthemeeting, 59.9 percent of Basilea's share capital was represented.

The shareholders approved the annual report, the financial statements andconsolidated financial statements for the business year 2012, anddischarged themembers of the Board of Directors and Management. Shareholders alsoapprovedcarrying forward the accumulated deficit.

In addition, Dr. Martin Nicklasson was elected to the Board of Directorsfor aterm of three years. Basilea's Board of Directors now comprises sevennon-executive members: Dr. Martin Nicklasson, Mr. Hans-Beat Gürtler,Prof. DanielLew, Dr. Thomas M. Rinderknecht, Mr. Domenico Scala, Mr. Steven D. SkolskyandDr. Thomas Werner. The Board of Directors elected Dr. Nicklasson asChairman ofthe Board and Domenico Scala as Vice-Chairman.

The shareholders re-elected PricewaterhouseCoopers AG, Basel, as StatutoryAuditors for the audit of the stand-alone and the consolidated financialstatements for the business year 2013.

Basilea's shareholders approved the proposal of HBM Healthcare Investments(Cayman) Ltd., holding 24.97 percent of the company's shares, to distributeCHF5.00 per share corresponding to approximately CHF 48 million from capitalcontribution reserves to shareholders. The payment will be made on June21, 2013. The last trading day to participate in the distribution will beApril 10, 2013. Starting from the ex-date of April 11, 2013, Basilea shareswillbe traded without the right to participate in the distribution.

In his presentation to shareholders, Chief Executive Officer Ronald Scottstated: "We achieved significant milestones in 2012 and successfullyfocused onour core area of overcoming resistance in anti-infectives and oncology. Thecompany is uniquely positioned to potentially create significant value forourshareholders as we move closer to the important milestones in the secondhalf ofthis year: the potential approval of our antibiotic ceftobiprole in Europeaswell as the first phase 3 results for our antifungal isavuconazole."

The Board and Management expressed their sincere thanks to the retiringBoardmembers Werner Henrich, Chairman since the company's inception, and ClaudeSchreiner, Board Member since 2007, for their invaluable contributions.

Ronald Scott commented: "With his strategic vision, extensive experience indeal-making and outstanding commitment, Werner Henrich has passionatelyworkedas our Chairman to build and grow the company for more than a decade.ClaudeSchreiner's wide-ranging industry experience was instrumental in creatingthesignificant value of Toctino which we were able to achieve for shareholdersthrough our transaction with Stiefel/GSK last year."

With the addition of Dr. Nicklasson to the Board, the Board is convincedthatBasilea is well positioned to continue its path as one of the leadingbiopharmaceutical companies addressing the growing medical need of drugresistance.

About Basilea

Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, andlisted onthe SIX Swiss Exchange (SIX: BSLN). Through the fully integrated researchanddevelopment operations of its Swiss subsidiary Basilea PharmaceuticaInternational Ltd., the Company focuses on innovative pharmaceuticalproducts inthe therapeutic areas of bacterial infections, fungal infections andoncology,targeting the medical challenge of rising resistance and non-response tocurrenttreatment options.


This communication expressly or implicitly contains certain forward-lookingstatements concerning Basilea Pharmaceutica Ltd. and its business. Suchstatements involve certain known and unknown risks, uncertainties and otherfactors, which could cause the actual results, financial condition,performanceor achievements of Basilea Pharmaceutica Ltd. to be materially differentfromany future results, performance or achievements expressed or implied bysuchforward-looking statements. Basilea Pharmaceutica Ltd. is providing thiscommunication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, futureevents or otherwise.

This press release can be downloaded from

Press release (PDF):

This announcement is distributed by Thomson Reuters on behalf ofThomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Basilea Pharmaceutica AG via Thomson Reuters ONE


Media Relations
Peer Nils Schroder, PhD
Head Public Relations &
Corporate Communications
+41 61 606 1102
Email Contact

Investor Relations
Barbara Zink, PhD, MBA
Head Corporate Development
+41 61 606 1233
Email Contact


Comment on this story